Flow Cytometry and Cell Sorting Facility

项目摘要--流式细胞仪和细胞分选设施 艾布拉姆森癌症中心(ACC)的流式细胞术和细胞分选设施已连续 自1981年以来，由NCI癌症中心支持补助金资助。该设施被公认为全球领先的 在细胞学和细胞学中，是最大和最全面的学术流式细胞术共享之一 北美的资源。提供全方位的细胞学服务，包括最高可达 30个参数、胞外小泡的检测和分析、基本和超稀有细胞分选、单细胞 多组分析、计算细胞数据分析、永久数据存档、专家咨询和 综合教育计划。Jonni Moore，博士，病理学和实验室医学教授， 免疫学博士，自1990年以来一直指导该设施。她是2020-2022年的 国际细胞学促进会(ISAC)，深度表型和 胞外囊泡细胞术，以及在共享资源操作方面备受尊敬的专家。领导层 团队还包括Thomas Williams，BS，SCYM(ASCP)CM，新任运营技术总监和 客户服务，拥有30多年的共享资源领导经验。Derek Jones，博士，SCYM(ASCP)CM， 新的研究和开发主任，是最近被选为ISAC共享的免疫学博士 资源新兴领导者。这个团队得到了其他8名全职同等工作人员的支持，平均 有15年的工作经验。凭借尖端的细胞技术和仪器，以及广泛的专业知识， ACC成员可以获得完整的实验设计和技术支持、数据分析和 释义。在本期间，该机制继续出现显著增长，反映出 最近在癌症研究中对基于细胞的分析产生了更大的兴趣。行政协调委员会成员占255个成员中的113个 在本报告期间(2018年7月1日至2019年6月30日)使用该设施的研究人员(44%)。这个 设施支持多项高影响研究，包括阐明免疫学和临床反应 阻断PD-1导致新的机制洞察力并引发新的临床试验(Huang等人，NAT Med，2019；Huang等人，自然，2017)。该机制的成功可归因于以下几个因素：雇用 以及留住高素质的工作人员(通过为共享资源实验室工作人员创建一个新的职业轨道)； 不断评估和随后购买最尖端的仪器；使用卫星 设施，可全天候访问，有目的地位于主要用户群附近；实施高效的 培训计划；主要运营IT支持(在线调度、数据集中归档、站点许可 向调查人员提供软件，以便在他们的实验室进行数据分析)。这导致了极具成本效益的 该行动为ACC调查人员提供了世界一流的细胞学专业知识。

PROJECT SUMMARY – Flow Cytometry and Cell Sorting Facility The Flow Cytometry and Cell Sorting Facility at the Abramson Cancer Center (ACC) has been continuously funded by the NCI Cancer Center Support Grant since 1981. The Facility is recognized as a worldwide leader in cytometry and cytomics and is one of the largest and most comprehensive academic flow cytometry Shared Resources in North America. A full range of cytomic services is offered including analytical cytometry of up to 30 parameters, detection and analysis of extracellular vesicles, basic and ultra-rare cell sorting, single cell multiomic analysis, computational cytomic data analysis, permanent data archive, expert consultation, and a comprehensive education program. Jonni Moore, PhD, Professor of Pathology and Laboratory Medicine with a doctorate in immunology, has directed the Facility since 1990. She is the 2020-2022 President of the International Society for the Advancement of Cytometry (ISAC), a noted expert in deep phenotyping and extracellular vesicle cytometry, and a highly respected expert in Shared Resource operation. The leadership team also includes Thomas Williams, BS, SCYM(ASCP)CM, the new Technical Director of Operations and Client Services, with more than 30 years of Shared Resource leadership. Derek Jones, PhD, SCYM(ASCP)CM, the new Director for Research and Development, is an immunology PhD recently selected as an ISAC Shared Resource Emerging Leader. This team is supported by eight other full time-equivalent staff with an average of 15 years' experience. With cutting-edge cytomic technology and instrumentation, and extensive expertise, ACC members have access to complete experimental design and technical support, data analysis and interpretation. During the current period, the Facility continued to experience significant growth, reflecting the recent expanded interest in cell-based analysis in cancer research. ACC members accounted for 113 of 255 researchers (44%) who used the Facility during this reporting period (July 1, 2018 through June 30, 2019). The Facility supported multiple high impact studies, including the elucidation of immunological and clinical response to PD-1 blockade leading to novel mechanistic insights and provoking new clinical trials (Huang et al., Nat Med, 2019; Huang et al., Nature, 2017). The success of the Facility can be attributed to several factors: hiring and retaining highly qualified staff (by creating a new career track for Shared Resource laboratory staff); constant evaluation and subsequent purchase of the most cutting-edge instrumentation; the use of satellite facilities, with 24/7 access, purposefully located near major user groups; implementation of a highly effective training program; major operational IT support (on-line scheduling, central archiving of data, site-licensing software to investigators to perform data analysis in their laboratories). This results in a highly cost-effective operation offering ACC investigators access to world class expertise in cytomics.